利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

10 条记录 (耗时 0.023 秒)

    Pyridyloxymethyl and benzisoxazole azabicyclic derivatives
    1.
    发明授权
    Pyridyloxymethyl and benzisoxazole azabicyclic derivatives 失效
    吡啶氧基甲基和苯并异恶唑氮杂双环衍生物

    公开(公告)号：US07345038B2

    公开(公告)日：2008-03-18

    申请号：US10800328

    申请日：2004-03-12

    申请人： Gene Michael Bright ,  Michael A. Brodney ,  Bishop Wlodecki

    发明人： Gene Michael Bright ,  Michael A. Brodney ,  Bishop Wlodecki

    IPC分类号： A01N43/00 ,  A01N43/58 ,  A01N43/60 ,  A61K31/55 ,  A61K31/50

    CPC分类号： C07D471/04

    摘要： An aminomethylpyridyloxymethyl/benzisoxazole substituted azabicyclic compound of formula I, pharmaceutical composition comprising same, and a method of treating one or more CNS or other disorders, including concurrent treatment of disorders such as schizophrenia and depression, wherein formula I is or a pharmaceutically acceptable salt or thereof, wherein Z is wherein Y is methylene; X is oxygen; n is 0; R1 and R2 are each hydrogen or halogen; and R3 and R4 together with the nitrogen atom to which they are attached form i) a saturated non-aromatic 3 to 7 membered monocyclic ring, said ring i) being unsubstituted or substituted or substituted with one or more (C1–C4)alkyl, (C1–C4)alkoxy(C1–C4)alkyl, or hydroxy groups.

    摘要翻译： 式I的氨基甲基吡啶氧基甲基/苯并异恶唑取代的氮杂双环化合物，包含其的药物组合物和治疗一种或多种CNS或其它病症的方法，包括同时治疗诸如精神分裂症和抑郁症的病症，其中式I是或其药学上可接受的盐或 其中Z是其中Y是亚甲基; X是氧; n为0; R 1和R 2各自为氢或卤素; 和R 3和R 4与它们所连接的氮原子一起形成i）饱和的非芳香族3至7元单环，所述环i）为 未取代或取代或被一个或多个（C 1 -C 4 -C 4）烷基取代的（C 1 -C 4 - 或烷氧基（C 1 -C 4 -C 4烷基）或羟基。

    Azabicyclic amine histamine-3 receptor antagonists
    4.
    发明申请
    Azabicyclic amine histamine-3 receptor antagonists 审中-公开
    偶氮二胺组胺3受体拮抗剂

    公开(公告)号：US20060047114A1

    公开(公告)日：2006-03-02

    申请号：US11212268

    申请日：2005-08-26

    申请人： Bishop Wlodecki

    发明人： Bishop Wlodecki

    IPC分类号： C07D417/02 ,  C07D403/02 ,  C07D413/02

    CPC分类号： C07D209/02 ,  C07D209/52

    摘要： This invention is directed to compounds of the formula I as defined herein, or a pharmaceutically acceptable salt thereof; a pharmaceutical composition containing a compound of formula I, a method of treatment of a disorder or condition that may be treated by antagonizing histamine H3 receptors, the method comprising administering to a mammal in need of such treatment a compound of formula I as described above, and a method of treatment of a disorder or condition selected from the group consisting of depression, mood disorders, schizophrenia, anxiety disorders, Alzheimer's disease, attention-deficit disorder (ADD), attention-deficit hyperactivity disorder (ADHD), psychotic disorders, sleep disorders, obesity, dizziness, epilepsy, motion sickness, respiratory diseases, allergy, allergy-induced airway responses, allergic rhinitis, nasal congestion, allergic congestion, congestion, hypotension, cardiovascular disease, diseases of the GI tract, hyper and hypo motility and acidic secretion of the gastrointestinal tract, the method comprising administering to a mammal in need of such treatment a compound of formula I as described above.

    摘要翻译： 本发明涉及本文定义的式I化合物或其药学上可接受的盐; 含有式I化合物的药物组合物，治疗可通过拮抗组胺H3受体治疗的病症或病症的方法，所述方法包括向需要这种治疗的哺乳动物施用如上所述的式I化合物， 以及治疗选自抑郁症，情绪障碍，精神分裂症，焦虑症，阿尔茨海默氏病，注意力缺陷障碍（ADD），注意缺陷多动障碍（ADHD），精神障碍，睡眠中的障碍或病症的方法 疾病，肥胖，头晕，癫痫，晕车，呼吸系统疾病，过敏，过敏引起的气道反应，过敏性鼻炎，鼻充血，过敏充血，充血，低血压，心血管疾病，胃肠道疾病，超低运动性和酸性 分泌胃肠道，该方法包括向需要这种治疗的哺乳动物施用形式的化合物 如上所述。

    Quinoline derivatives
    5.
    发明授权
    Quinoline derivatives 失效
    喹啉衍生物

    公开(公告)号：US06894062B1

    公开(公告)日：2005-05-17

    申请号：US10664706

    申请日：2003-09-18

    申请人： Bishop Wlodecki ,  Gene M. Bright

    发明人： Bishop Wlodecki ,  Gene M. Bright

    IPC分类号： A61K31/47 ,  C07D401/02 ,  C07D401/04

    CPC分类号： C07D401/04

    摘要： The present invention relates to compounds of Formula I, wherein R1, R2, R3, R4, and n are as defined, and to pharmaceutically acceptable salts of said compounds. Compounds of Formula I have activity in agonizing 5HT7 receptors and are useful in treating, for example, disorders that can be treated by modulating circadian rhythms.

    摘要翻译： 本发明涉及式I化合物，其中R 1，R 2，R 3，R 4， ，和n如上定义，以及所述化合物的药学上可接受的盐。 式I的化合物在激动5HT7受体中具有活性，并且可用于治疗例如可通过调节昼夜节律治疗的病症。

    Diazabicyclic histamine-3 receptor antagonists
    6.
    发明申请
    Diazabicyclic histamine-3 receptor antagonists 审中-公开
    二氮杂双环组胺3受体拮抗剂

    公开(公告)号：US20050282811A1

    公开(公告)日：2005-12-22

    申请号：US11152273

    申请日：2005-06-14

    申请人： Harry Howard ,  Bishop Wlodecki

    发明人： Harry Howard ,  Bishop Wlodecki

    IPC分类号： A61K31/498 ,  C07D471/04 ,  C07D487/04

    CPC分类号： C07D471/04

    摘要： This invention is directed to compounds of the formula I and II as defined herein, or a pharmaceutically acceptable salt thereof; a pharmaceutical composition containing a compound of formula I or II, a method of treatment of a disorder or condition that may be treated by antagonizing histamine H3 receptors, the method comprising administering to a mammal in need of such treatment a compound of formula I or II as described above, and a method of treatment of a disorder or condition selected from the group consisting of depression, mood disorders, schizophrenia, anxiety disorders, Alzheimer's disease, attention-deficit disorder (ADD), attention-deficit hyperactivity disorder (ADHD), psychotic disorders, sleep disorders, obesity, dizziness, epilepsy, motion sickness, respiratory diseases, allergy, allergy-induced airway responses, allergic rhinitis, nasal congestion, allergic congestion, congestion, hypotension, cardiovascular disease, diseases of the GI tract, hyper and hypo motility and acidic secretion of the gastro-intestinal tract, the method comprising administering to a mammal in need of such treatment a compound of formula I or II as described above.

    摘要翻译： 本发明涉及如本文所定义的式I和II的化合物或其药学上可接受的盐; 含有式I或II化合物的药物组合物，治疗可通过拮抗组胺H3受体治疗的病症或病症的方法，所述方法包括向需要这种治疗的哺乳动物施用式I或II化合物 以及治疗选自抑郁症，情绪障碍，精神分裂症，焦虑症，阿尔茨海默氏病，注意力缺陷障碍（ADD），注意力缺陷多动障碍（ADHD） 过敏反应，过敏性鼻炎，鼻充血，过敏性充血，充血，低血压，心血管疾病，胃肠道疾病，过氧化物酶，过氧化物酶 胃肠道的运动不足和酸性分泌，所述方法包括向需要这种治疗的哺乳动物施用com 磅如式I或II所述。

    Histamine-3 agonists and antagonists
    7.
    发明申请
    Histamine-3 agonists and antagonists 审中-公开
    组胺-3激动剂和拮抗剂

    公开(公告)号：US20060014733A1

    公开(公告)日：2006-01-19

    申请号：US11155085

    申请日：2005-06-16

    申请人： Harry Howard ,  Bishop Wlodecki

    发明人： Harry Howard ,  Bishop Wlodecki

    IPC分类号： A61K31/55 ,  A61K31/541 ,  A61K31/5377 ,  A61K31/4545 ,  A61K31/454

    CPC分类号： C07D207/14 ,  C07D401/10 ,  C07D403/10 ,  C07D405/10 ,  C07D409/10

    摘要： This invention is directed to compounds of the formula I as defined herein, or a pharmaceutically acceptable salt thereof; a pharmaceutical composition containing a compound of formula I, a method of treatment of a disorder or condition that may be treated by antagonizing histamine H3 receptors, the method comprising administering to a mammal in need of such treatment a compound of formula I as described above, and a method of treatment of a disorder or condition selected from the group consisting of depression, mood disorders, schizophrenia, anxiety disorders, Alzheimer's disease, attention-deficit disorder (ADD), attention-deficit hyperactivity disorder (ADHD), psychotic disorders, sleep disorders, obesity, dizziness, epilepsy, motion sickness, respiratory diseases, allergy, allergy-induced airway responses, allergic rhinitis, nasal congestion, allergic congestion, congestion, hypotension, cardiovascular disease, diseases of the GI tract, hyper and hypo motility and acidic secretion of the gastro-intestinal tract, the method comprising administering to a mammal in need of such treatment a compound of formula I as described above.

    摘要翻译： 本发明涉及本文定义的式I化合物或其药学上可接受的盐; 含有式I化合物的药物组合物，治疗可通过拮抗组胺H3受体治疗的病症或病症的方法，所述方法包括向需要这种治疗的哺乳动物施用如上所述的式I化合物， 以及治疗选自抑郁症，情绪障碍，精神分裂症，焦虑症，阿尔茨海默氏病，注意力缺陷障碍（ADD），注意缺陷多动障碍（ADHD），精神障碍，睡眠中的障碍或病症的方法 疾病，肥胖，头晕，癫痫，晕车，呼吸系统疾病，过敏，过敏引起的气道反应，过敏性鼻炎，鼻充血，过敏充血，充血，低血压，心血管疾病，胃肠道疾病，超低运动性和酸性 分泌胃肠道，该方法包括向需要这种治疗的哺乳动物施用化合物 我如上所述。